![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to produce a novel prostate cancer therapy known as AB001 (212Pb-NG001), a promising therapy for prostate cancer, by utilizing SpectronRx's expertise and state-of-the-art facilities.
Lead Product(s): 212Pb-NG001
Therapeutic Area: Oncology Product Name: AB001
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: ARTBIO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 09, 2024